Cytophage Technologies Ltd. · LS:A4ZZ0X
Cytophage Technologies — Investor Presentation (May 2026)
35 slides from Cytophage Technologies's investor presentation, May 2026
Slide 1: Corporate Presentation May 2026
CO R P O R AT E P R E S E N TAT I O N May 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except fo
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Drug-resistant infections caused by overuse of antibiotics has accelerated the demand for bacteriophage-based solutions, (safe, non-toxic and biological) Pioneers in bacteriophage R&D and production, with track- record of international competitive awards De-risked, replicable t
Slide 4: A Global Health Crisis
A GLOBAL HEALTH CRISIS Leading Cause of Death by 2050 3,500 people die every day from drug-resistant infections; Deadly E. coli outbreak linked to projected to exceed 10 million deaths per year by 2050. McDonald’s Quarter Pounder burger October 23, 2024 Economic Damage Drug resistance could cause an
Slide 5: One Health – Integrated Approach Required
ONE HEALTH – INTEGRATED APPROACH REQUIRED How resistant bacteria move through our supply chain Antibiotic resistant bacteria Environmental contamination with on harvested foods antibiotic resistant bacteria Use of antibiotics on farm Antibiotic resistant Antibiotic resistant animals can promote bact
Slide 6: Bacteriophages – Natural Predators
BACTERIOPHAGES – NATURAL PREDATORS NATURE’S DEFENSE AGAINST BACTERIA How do bacteriophages work? • Most abundant form of life on earth • Bacteria’s natural predators • Viruses that only infect and kill bacteria cytophage.com 6
Slide 7: The Cytophage Solution
THE CYTOPHAGE SOLUTION Leveraging bacteria’s natural predators for commercially applicable solutions. • Safe and toxin free • GMP capabilities • Lytic life cycle only near completion • 1000’s of strains in CYTOPHAGE MANUFACTURING Cytophage library CYTOPHAGE PHAGES Natural phage CYTOPHAGE TOOLS • Lar
Slide 8: Cytophage to Date
CYTOPHAGE TO DATE FOUNDED 2016 PRESTIGIOUS WINS SINCE RTO FEB 2024 • Leading scientific staff PRODUCT DEVELOPMENT recruited from Canada’s Completed two pilot studies in Europe for National Microbiology AviPhage product 2025 Lab and the extensive REGULATORY APPROVALS Company of the Year R&D labou
Slide 9: Go To Market Strategy: Animal Health and Human Health
GO TO MARKET STRATEGY 1 A N I M A L H E A LT H 2 H U M A N H E A LT H Faster Trials Long Timeframe FDA trial phases seen as only benchmark of success – without regulatory red tape yet trial can be timeframe of 7 - 10 years Lower Trial Costs Capital Intensive Capital intensive process that is difficu
Slide 10: Animal Health
ANIMAIHEALTH —
Slide 11: Market Entry - Poultry
MARKET ENTRY - POULTRY Strategic Rationale Current and Alternative Treatments RESTRICTIONS IN KEY MARKETS Program Type Description Performance • 80% of poultry antibiotics already restricted in key Antibiotics + Conventional ionophores for growth Best Feed Conversion Ratio markets Antibiotic enhance
Slide 12: Poultry Health Products – Four Pillars
POULTRY HEALTH PRODUCTS – FOUR PILLARS BROILERS EGGS CARCASS/MEAT LAYERS AviPhage OvaPhage PhageFend AviPhage Initial Target Market Initial Target Market New Market Future Market Salmonella / E.coli Salmonella / Shigella 2025 AviPhage European 2025 OvaPhage Egg Trial 2025 PhageFend 2026 AviPhage for
Slide 13: 2025 European Union Phage Trials
BROILERS AviPhage 2025 EUROPEAN UNION PHAGE TRIALS Initial Target Market Salmonella / Closed barn with E.coli PILOT IMPACT biosecurity (2025) UNTREATED RESULTS Mortality (%) 2.6 1.7 35% FEWER DEATHS IN THE FLOCK No. birds weighed at trial end 961 932 Total Meat Recovered (kg) 1121.68 1092.82 MORE
Slide 14: 2023 South East Asia Phage Trial
BROILERS AviPhage 2023 SOUTH EAST ASIA PHAGE TRIAL Initial Target Market Salmonella / E.coli Open air barn, PILOT no biosecurity RESULTS IMPACT UNTREATED DAYS TO MARKET 34 32 2 DAYS BIRDS TO MARKET EARLIER No. BIRDS SOLD (%) 88.6% 91.2% 2.6 % MORE BIRDS SENT TO MARKET TOTAL BODY WEIGHT (KG) 1113
Slide 15: 2023 South East Asia Phage Trial Results
BROILERS AviPhage 2023 SOUTH EAST ASIA PHAGE TRIAL RESULTS Initial Target Market Aviphage Outperforms Untreated Sample Group With Visible Improvements Salmonella / Within 11 Days E.coli Untreated DAY 11 DAY 11 DAY 3 cytophage.com 15
Slide 16: European Union – Next Steps
BROILERS EUROPEAN UNION – NEXT STEPS AviPhage TO DATE Initial Target 2025 Q2 Q3 Q4 2026 Q2 Market • Strong local partnership Salmonella / (two large farms, influential entrepreneurs) $1.55M FINANCING E.coli • Two pilot studies completed MAY TRIAL (in accordance with rigid scientific protocols ) • St
Slide 17: 2024 Canada Laboratory Data & 2025 Study
EGGS 2024 CANADA LABORATORY DATA & 2025 STUDY OvaPhage Initial Target Market RESULTS OvaPhage Salmonella / Shigella has received Salmonella (%) Shigella (%) 100.00 100.00 Health Canada regulatory approval (LONO) 75.00 75.00 99%+ 99%+ reduction reduction NEXT STEPS 50.00 50.00 25.00 25.00 Ongoing Inc
Slide 18: 2023 Canada Laboratory Data
Surface of Carcass/Meat 2023 CANADA LABORATORY DATA Products PhageFend RESULTS PhageFend Initial Target Market has received Salmonella Phage Treatment of Chicken (Low and High Dose) Health Canada regulatory approval (LONO) Low-Dose: ~ ½ log reduction High-Dose: ~ 3 log reduction NEXT STEPS • Current
Slide 19: Human Health
HUMAN HEALTH
Slide 20: Landmark Use of Bacteriophage in Canada
LANDMARK USE OF BACTERIOPHAGE IN CANADA November 2023 • One of Dr. Azad’s patients suffered from a severe antibiotic-resistant infection following a joint replacement • With no viable treatment options, the patient faced amputation or death February 2024 • Cytophage delivered a personalized bacterio
Slide 21: Mainstreaming Phage Therapy
MAINSTREAMING PHAGE THERAPY • Cytophage receiving approval from Health Canada for AviPhage and PhageFend August 26, 2025 • “How naturally occurring viruses could help treat superbug infections” December 1, 2023 • “This is my last resort’, Ottawa-area woman says of experimental phage therapy to treat
Slide 22: Partnerships Drive Clinical Innovation
PARTNERSHIPS DRIVE CLINICAL INNOVATION Streamlined access to Patient Identification patients best suited to phage therapy PARTNERSHIP WITH THE ORTHOPEDIC INNOVATION CENTRE AT THE CONCORDIA Real-world feedback on HIP & KNEE INSTITUTE Operational Insights deploying treatments in clinical settings Resu
Slide 23: Human Phage Therapy
HUMAN PHAGE THERAPY I L L U S T R AT I V E T I M E L I N E C Y T O P H A G E S T R AT E G Y Work Flow (Months) 1 2 3 4 FOCUSED ON THE GROWING CHALLENGE OF Bacterial Isolate PROSTHETIC JOINT INFECTIONS Acquisition • Annual hospital costs for PJI will reach nearly Bacterial Analysis US$2 billion by 20
Slide 24: Commercial Approach
COMMERCIAL APPROACH
Slide 25: Large Addressable Markets & Powerful Trends
LARGE ADDRESSABLE MARKETS & POWERFUL TRENDS Large addressable markets Powerful global trends • $100bn antibiotic market for humans • 70 countries with antibiotic restrictions • 86 countries with national action plans for AMR • $5BN antibiotic market for poultry • Increasing number of multinational a
Slide 26: Growth Model & Potential Catalysts
GROWTH MODEL & POTENTIAL CATALYSTS PRODUCT SETS 2023 2024 2025 Catalysts & Milestones POULTRY – Broiler Chickens Total Addressable 2025 Expected 2026 Market AviPhage AviPhage + $2 billion • Continuing progression • Expand global market POULTRY – Eggs in development of EU targeting regulatory- regula
Slide 27: Illustrative Financial Model
ILLUSTRATIVE FINANCIAL MODEL REVENUE RAMP: BROILER CHICKENS (AviPhage only) BASE CASE: $40M - $50M ANNUAL REVENUE • $2 billion addressable market • Target 2026: Significant ramp up of AviPhage revenue with multiple large customers being onboarded • AviPhage (Broiler chickens) is first product: OvaPh
Slide 28: State-of-the-Art Facility
STATE-OF-THE-ART FACILITY 20,585 sq ft company headquarters (June 2024) State-of-the-art lab space Modular manufacturing unit Office space Cost effective construction and outfitting – Total Cost $1.5M Continued enhancements underway • Expanded lyophilizer and autoclave capabilities • Packaging and l
Slide 29: Non-Dilutive Funding Sources
NON-DILUTIVE FUNDING SOURCES Historic Wins/Funding ($1M+) Targeted Grants ($5-10M) • Nutreco Feedtech Challenge • Strategy developed for applying for non-dilutive grants from public and private funding • Canadian Falling Walls Lab pitch organizations competition • Targeting AMR and infectious diseas
Slide 30: Corporate Information
CORPORATE INFORMATION
Slide 31: Management Team
MANAGEMENT TEAM DR. STEVEN THERIAULT JAMES KINLEY Chief Executive Officer, Chief Financial Officer Chief Science Officer, Director • Extensive experience in the biotech industry • PhD Synthetic Biology with 25 years of • Served as a CFO to several publicly listed research experience healthcare compa
Slide 32: Board of Directors
BOARD OF DIRECTORS TOM WELLNER MICHAEL COCHRANE Chairman Director • Over three decades of global experience in biotechnology, pharmaceutical, • Investment banking veteran with more than 30 years of M&A and finance and healthcare services companies experience in both New York and Toronto • led health
Slide 33: Capital Structure
CAPITAL STRUCTURE Capitalization (CYTO.V) Shares Outstanding 67,870,221* Options / RSUs Outstanding 5,816,375 Warrants Outstanding 17,839,390 Fully Diluted S/O 91,519,986 Options Warrants Strike: < $0.28 1,500,000 Strike: $0.40 10,971,415 Strike: $0.35 – $1.30* 2,868,875 Strike: $0.50 5,000,000 Stri
Slide 34: Investment Highlights
INVESTMENT HIGHLIGHTS Drug-resistant infections caused by overuse of antibiotics has accelerated the demand for bacteriophage-based solutions, (safe, non-toxic and biological) Pioneers in bacteriophage R&D and production, with track- record of international competitive awards De-risked, replicable t
Slide 35: Thank You
THANK YOU “ Bacteriophages: The Silent Cure to Antimicrobial Resistance” TEDx Winnipeg, 2025 IR@cytophage.com www.cytophage.com
Cytophage Technologies — Investor Presentation (May 2026) on 6ix